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Abstract: Fragment-based drug discovery is now widely adopted for 
lead generation in the pharmaceutical industry. However, fragment 
screening collections are often predominantly populated with flat, 2-D 
molecules. Herein, we describe a workflow for the design and 
synthesis of 56 3-D disubstituted pyrrolidine and piperidine fragments 
that occupy under-represented areas of fragment space (as 
demonstrated by a principal moments of inertia (PMI) analysis). A key, 
and unique, underpinning design feature of this fragment collection is 
that assessment of fragment shape and conformational diversity (by 
considering conformations up to 1.5 kcal mol-1 above the energy of 
the global minimum energy conformer) is carried out prior to synthesis 
and is also used to select targets for synthesis. The 3-D fragments 
were designed to contain suitable synthetic handles for future 
fragment elaboration. Finally, by comparing our 3-D fragments with 
six commercial libraries, it is clear that our collection has high three-
dimensionality and shape diversity.  
Introduction 
Over the past 20 years, fragment-based drug discovery (FBDD) 
has developed into a well-established method for hit and lead 
generation.[1] To date, three approved anti-cancer drugs, 
Vemurafenib,[2] Venetoclax[3] and Erdafitinib[4] have originated 
from FBDD campaigns, with 30 additional compounds having 
entered clinical trials.[5] Due to the low molecular weight (MW) of 
fragments (MW typically < 300 Da),[6] establishing and employing 
a fragment library that can effectively sample chemical space 
(typically a few thousand compounds) is far cheaper and more 
straightforward than establishing a high-throughput screening 
library.[1d,5,7] However, due to their small size, care must be taken 
with the design of fragment libraries to make them suitable for the 
generation of high quality starting points for drug. 
Although the physicochemical properties of fragment libraries 
often follow the widely accepted ‘rule-of-three’,[6] little attention is 
generally paid to shape diversity within fragment collections – 
indeed, sp2 rich compounds with planar, aromatic ring systems 
predominate.[8–10] 3-D fragments are increasingly being 
considered as complementary to their 2-D counterparts and as 
crucial components of well-rounded screening libraries[8,11,12] 
since they improve the coverage of chemical space and the 
overall diversity of the library. Of course, it is possible that, being 
more complex than their planar counterparts, 3-D fragments 
would lead to reduced hit rates.[7,13] However, the use of 3-D 
fragments may offer advantages in terms of pharmacophore 
coverage and solubility, leading to better starting points for lead 
generation.[1d,14,15] It has also been suggested that a highly shape 
diverse library could display a broader range of biological 
activities and be useful in generating hits for challenging 
targets.[8,9] 
To meet this developing need for representation of 3-D 
compounds in fragment libraries, there have been several reports 
on the synthesis of 3-D fragments,[16,17] including the use of 
diversity oriented synthesis,[9,12,18] and natural product-based 
approaches [10,19] as well as a set of fluorinated fragments.[20] 
Furthermore, several 3-D fragment libraries are commercially 
available (e.g. Life Chemicals 3D Fragment Library, ChemDiv 3D 
FL Fragment Library, Enamine 3D Shape Diverse Fragment 
Library). In most cases, the assessment of the three-
dimensionality of commercial 3-D libraries is performed by 
analyzing the fraction of sp3 carbons (Fsp3) and, whilst it has been 
shown that increasing Fsp3[14] and controlling the number of 
aromatic rings[21] in a potential drug candidate can aid drug 
RESEARCH ARTICLE    
2 
 
development, these descriptors are poor surrogates for 
measuring the three-dimensionality of a molecule.[7] Two 
commonly used methods for assessing 3-D shape are plane-of-
best-fit[22] and principal moments of inertia (PMI)[23] analysis. In 
both cases, the 3-D shape of molecular mechanics-computed 
global minimum energy conformers of molecules can be easily 
compared and there is a good correlation between plane-of-best-
fit and PMI analyses.[22] In contrast, and perhaps unsurprisingly, it 
has been shown that plane-of-best-fit does not correlate with Fsp3 
for a wide range of medicinally-relevant compounds.[22] To further 
validate the argument that use of Fsp3 as a surrogate for three-
dimensionality is flawed, we assessed the correlation between 
Fsp3 and PMI for sets of fragments. Analysis of six commercially 
available 2-D and 3-D fragment libraries was performed by 
calculating PMI values for a random 1000 compounds (for each 
library) and comparing with Fsp3. No correlation was found (see 
SI for details). Furthermore, PMI analysis of these six 
commercially available fragment libraries showed that the 3-D 
libraries (typically designed using Fsp3 as a guide) have only a 
marginally better 3-D profile compared to the standard 2-D rich 
commercial fragment libraries (see SI for a detailed analysis). 
Given that most commercial fragment libraries appear to contain 
a limited number of 3-D shaped fragments, we set out to 
synthesise a library of ~50 3-D fragments that would specifically 
occupy the under-represented areas of fragment space (as 
determined by PMI analyses of the conformations of fragments). 
Our 3-D collection would be available to supplement commercially 
available screening collections and thereby provides alternative 
starting points in FBDD programs. At the outset, the following key 
design criteria for our workflow were devised: (i) 3-D fragments 
would be based on disubstituted pyrrolidines and piperidines 
since these heterocycles are ubiquitous in bioactive molecules, 
being the most common five- and six-membered ring nitrogen 
heterocycles found in FDA-approved drugs;[24] (ii) 3-D fragments 
would be designed to possess properties broadly within ‘rule-of-
three’ fragment space (MW < 300 Da, ClogP < 3, number of 
hydrogen bond acceptors (HBA) and donors (HBD) ≤ 3);[6] (iii) 3-
D shape analysis using PMI plots would be an integral part of the 
3-D fragment design protocol and used to select compounds for 
synthesis to ensure that we were targeting novel fragment space; 
(iv) uniquely, conformational diversity of 3-D fragments would be 
achieved by assessing the 3-D shape of all conformations up to 
1.5 kcal mol-1 above the energy of the global minimum energy 
conformer for each fragment; (v) all of the 3-D fragments would 
be synthesis-enabled via a readily functionalisable secondary 
amino group. Of note, design criteria (iii) and (iv) are distinct to 
previous approaches[8,9,17b,17c,17f,17g] where PMI analysis of global 
minimum energy conformers is used, mostly retroactively, to 
assess 3-D shape. Herein, using design criteria (i)-(iv), we report 
the design, synthesis and analysis of a unique collection of 56 
shape-diverse pyrrolidine and piperidine 3-D fragments. 
Results and Discussion 
Our overall approach was to design a set pyrrolidine and 
piperidine 3-D fragments and to select compounds for synthesis 
by considering the computational PMI analysis of the 3-D shape 
of their conformations up to 1.5 kcal mol–1 above the energy of the 
global minimum energy conformer. Although the choice of 1.5 kcal 
mol–1 had an arbitrary element, we were keen to consider 
accessible conformations – for example, at 37 °C, a conformer 
that was 1.5 kcal mol-1 above the energy of the global minimum 
energy conformer would be present in ~8%. Thus, to start, we 
virtually enumerated and analysed all possible regio- and 
diastereomers arising from pyrrolidine scaffold 1 (Fig. 1A), 
substituted with an ester and a methyl group, and from piperidine 
scaffold 2 (Fig. 1B), substituted with a hydroxymethyl and a 
methyl group. Both scaffolds were decorated with either an acetyl, 
mesyl, methyl or proton at the nitrogen, giving 56 and 92 possible 
racemic or achiral isomers for 1 and 2 respectively.[25] Despite 
such apparently simple design criteria, the majority of these 148 
compounds were in fact novel. Representative 3-D fragments 
include pyrrolidines 1a, 1g, 1i and 1l and piperidines 2b, 2j, 2l and 
2r (Fig. 1A and 1B). It was envisaged that this approach would 
lead to a wide range of shape-diverse fragments with two potential 
protein binding groups in addition to a hydrophobic methyl group. 
For these scaffolds, using a Pipeline Pilot protocol described in 
the SI, we calculated and constructed the PMI plot for all 955 
conformers (582 for 1 and 373 for 2) up to 1.5 kcal mol-1 above 
the energy of the global minimum energy conformer for each of 
the 148 compounds (Fig. 1A and 1B, red dots are global minimum 
energy conformers and blue dots are higher energy 
conformers[26]). With triangular PMI plots of the normalized PMIs 
(NPR1 versus NPR2), the three apexes correspond to disc 
(bottom), rod (top-left) and spherical (top-right) shapes; lines 
parallel to the rod-disc axis correspond to ΣNPR values (where 
ΣNPR = NPR1 + NPR2, ranging from 1.00-2.00). Conformations 
that lie furthest from this rod-disc axis (in which ΣNPR = 1.00), will 
be of interest as they deviate the most from planarity. It is striking 
how the enumeration of a representative set of simple 
disubstituted pyrrolidines and piperidines leads to such a high 
degree of shape diversity of both the global minimum energy and 
higher energy conformations (Fig. 1A and 1B) – clearly, elaborate 
and structurally complex molecules are not a requirement for 
shape diversity. Using the PMI plots in Fig. 1A and 1B, 3-D 
fragments furthest from the rod-disc axis were selected for 
synthesis. For the pyrrolidines 1, 14 fragments with one or more 
conformer with ΣNPR ≥ 1.36 (Fig 1A, grey area) were selected, 
corresponding to the 25% most 3-D fragments. A similar selection 
criterion (ΣNPR ≥ 1.39) resulted in 19 piperidine fragments being 
chosen for synthesis and inclusion in the 3-D fragment collection.  
The PMI plot of these initially selected 33 pyrrolidines 1 and 
piperidines 2 (Fig. 1C) shows that the selected 3-D fragments 
have highly 3-D conformations and provide excellent coverage of 
3-D chemical space on the PMI plot. Unlike many fragment 
collections, there are no conformers occupying the rod-disc axis 
and very few within the first 10% of the PMI plot (ΣNPR < 1.10); 
there are no global minimum energy conformers in the ΣNPR 
1.00-1.10 region. Consideration of higher energy conformers 
provides greater conformer diversity (and therefore shape 
diversity) than if only the global minimum energy conformers are 
considered. For example, the lowest energy conformer of 
pyrrolidine 1l has pseudo-diequatorial substituents and is less 
three-dimensional (ΣNPR = 1.21) than a higher energy (but 
readily accessible) conformer with pseudo-diaxial substituents 
(ΣNPR = 1.38) (Fig 1C). Similarly, piperidine 2j exhibits 
diequatorial and diaxial conformers with significantly different 
degrees of three-dimensionality (ΣNPR = 1.19 and 1.48 
respectively).  




Figure 1. PMI analysis of potential fragments. A: Conformers of pyrrolidine scaffold 1 (top) and exemplar fragments (bottom). B: Conformers of piperidine scaffold 
2 (top) and exemplar fragments (bottom). Compounds with conformations within the grey areas were selected for synthesis. C: Conformers of 33 selected fragments 
(top) and global minimum energy and selected higher energy 3-D conformers of 1l and 2j. Red dots indicate global minimum energy conformers and blue dots 
indicate higher energy conformers.
The structures of the initially selected 3-D fragments 1a-1l and 
2a-2s are shown in Scheme 1, together with their associated 
synthetic routes (see SI for structures of all 33 selected 
fragments). The PMI-based compound selection protocol resulted 
in the identification of geminal disubstituted pyrrolidines 1a-e and 
piperidines 2a-e. Since this geminal disubstitution was present in 
all of these fragments, they were conveniently accessed through 
methylation of the enolates[27] of the requisite Boc protected 
esters 3, giving 4 in high yields, followed by simple functional 
group manipulations (Scheme 1A). For the 14 selected 
diastereomeric piperidines 2f-s, we envisaged that these 
fragments could be accessed through a unified approach 
employing an initial stereoselective hydrogenation of disubstituted 
pyridines 5 (Scheme 1B).[28] Treatment of pyridines 5 with 
hydrogen and 10-30 mol% PtO2 gave cis-piperidine esters 6 in 
good yields and 70:30 to >95:5 dr. The only exception was with a 
3,5-disubstituted piperidine which in fact gave the trans-piperidine 
ester 6 (and ultimately fragment 2q) as the major product.[29] 
Subsequent functional group interconversions converted the 
esters into hydroxymethyl groups and installed the requisite 
functionality on the secondary amine giving 14 fragments 2f-s; in 
the case of 2i, 2j, 2o and 2p, epimerisation of cis-esters to trans-
esters[30] using alkoxide bases was used to access the desired 
trans-isomers (see SI for full synthetic details). 
The remaining pyrrolidine fragments were accessed through 
different diastereoselective reduction processes, as detailed in 
Scheme 1C. First, intermediate 2,5-cis-pyrrolidine 8 was 
synthesised in 99% yield as a single diastereomer through Boc 
removal from 7 and diastereoselective reduction of the resulting 
cyclic iminium ion.[31] Subsequent acetylation gave fragment 1f. 
Similarly, reduction of keto-nitrile 9 proceeded via an iminium ion 
and (after N-benzylation) gave 2,4-cis pyrrolidine 10. N-Benzyl to 
N-methyl transposition gave fragment 11a, the tert-butyl ester 
analogue of an initially selected target compound.[32] 2,4-cis 
Pyrrolidine fragment 1g was accessed through stereoselective 
reduction of enamine 12 to pyrrolidinone 13 followed by functional 
group interconversions. Intermediates 7 and 12 are available in a 
single step from a common commercially available building 
block.[33] An intramolecular Pd-catalysed coupling of 14,[34] 
followed by hydrogenation of the resulting α,β-unsaturated ester 
with concomitant debenzylation gave 3,4-disubstituted pyrrolidine 
fragment 1h. Subsequent N-methylation gave fragment 1i. Finally, 
addition of α-methyl benzylamine to activated cyclopropane 16 
(synthesised from β-ketoester 15) gave dihydropyrrole 17.[35] 
Reduction[36] gave cis-pyrrolidine 18 in 72:25 dr, which was 
subsequently transformed into the desired 2,3-disubstituted 
fragments 1j-1l. This synthetic campaign resulted in the synthesis 
of 31 targeted 3-D fragments 1a-l and 2a-s, along with a tert-butyl 
ester analogue of a further fragment 11a. 
To further increase the library diversity and coverage of chemical 
space, we explored altering the potential protein binding groups. 
To this end, a further 24 3-D fragments that could be accessed 
from readily available building blocks in an expedient manner 
were synthesised (Fig. 2). Prior to synthesis, a PMI analysis was 
carried out on all targeted 3-D fragments to ensure that they had 
at least one conformation with ΣNPR value >1.10. 2,3-
Disubstituted piperidine 6a, itself a 3-D fragment, was first 
manipulated to give simple N-functionalised fragments 19a and 
19b. Alternatively, the ester group was modified to introduce other 
hydrogen bonding motifs to give nitriles 19c and 19d, alcohol 19e, 
ether 19f, amides 19g-j and acid 19k. Likewise, building block 6b 
was modified to give piperidines 20a-c. Further structural diversity 
was introduced into the collection through the modification of 
pyrrolidine building blocks 4a and 10, resulting in nine fragments 
21a-f and 11b-d. 
 
 




Scheme 1. Synthesis of selected 3-D fragments. 
 
Figure 2. Additional structurally diverse 3-D fragments. 
In total, a collection of 56 designed 3-D fragments encompassing 
medicinally-relevant disubstituted piperidines and pyrrolidines 
that targeted under-represented areas of fragment space was 
synthesised. Despite the simplicity of these fragments, it is 
notable that 42 are in fact novel molecules. Calculation of the 
physicochemical properties showed that almost all fragments 
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conformed to the ‘rule-of-three’ (Table 1). Of particular note, the 
mean lipophilicity of the collection (ClogP 0.54) is low in 
comparison with commercially available fragment libraries (see SI 
for full details), making these compounds excellent starting points 
for lead discovery programs.[37,38] The stability and solubility of the 
fragments was assessed to ensure that they were suitable for 
incorporation into a screening collection. Of the 56 fragments, 52 
fragments were stable to prolonged storage on the bench and in 
DMSO stock solutions (> 6 weeks). Of these, 48 fragments were 
stable in aqueous buffer for > 24 h. Crucially, 40 fragments were 
soluble at a concentration of > 0.5 mM in aqueous buffer (see SI) 
and are therefore suitable for biophysical screening.[1e] 
Table 1. Mean physicochemical properties of the synthesised 3-D fragment 
collection. 
Property[a] Ideal Range[b[ Calculated Values 
MW ≤ 300 173 ± 38 
ClogP ≤ 3 0.54 ± 0.55 
HBA ≤ 3 2.68 ± 0.73 
HBD ≤ 3 0.89 ± 0.70 
RBC ≤ 3 1.64 ± 0.77 
TPSA / Å2 ≤ 60 46.7 ± 19.1 
[a] MW = molecular Weight, HBA = number of hydrogen bond acceptors, HBD 
= number of hydrogen bond donors, RBC = rotatable bond count, TPSA = 
topological polar surface area. [b] ‘Rule-of-three’ guidelines.[5] 
The PMI plot of the 56 3-D fragments is shown in Figure 3A, 
clearly demonstrating that our fragments target conformations far 
from the rod-disc axis and with a wide-ranging spread throughout 
the plot. Finally, to show that our fragments targeted under-
represented area of fragment space, we compared this collection 
of 3-D fragments with six commercial fragment libraries, including 
three that were designed to be 3-D in nature (Life Chemicals 3D 
Fragment Library, ChemDiv 3D FL Fragment Library, Enamine 
3D Shape Diverse Fragment Library). Using a random selection 
of 1000 compounds from each of the six commercial fragment 
libraries, all conformers (up to 1.5 kcal mol-1 above the energy of 
the global minimum energy conformer) were generated (see SI 
for full details). Then, the mean distance from the rod-disc axis 
(ΣNPR) was determined for each fragment, based on its 
conformations. Figure 3B shows the cumulative percentage of 
fragments within a defined mean distance from the rod-disc axis 
(ΣNPR). The fact that our 3-D fragments are the furthest to the 
right on this plot highlight that they are more three-dimensional 
than even commercially available 3-D fragment libraries. 
Interestingly, visual inspection of some of the conformers showed 
the presence of internal hydrogen bonds. Since such conformers 
are unlikely to exist under physiological conditions, care must be 
taken to fully interrogate the conformations generated from such 
molecular mechanics-generated PMI analyses. It is clear that this 
is an inherent issue with all molecular shape analyses that depend 
upon simple conformer generation within computational software 
packages such as Pipeline Pilot. 
Conclusion 
In conclusion, we have developed a workflow to design and select 
3-D, rather than sp3-rich, fragments by generating global 
minimum energy conformers and low-energy conformers of 
potential fragments and assessing shape by PMI analysis. This 
approach leads to conformational diversity in addition to 3-D 
shape diversity. We have used this approach to generate a 
collection of 56 3-D fragments based on disubstituted pyrrolidine 
and piperidine cores that are suitable for inclusion into existing 
screening libraries and possess synthetic handles for fragment 
elaboration. The majority of fragments adhere to recommended 
‘rule-of-three’ guidelines for physicochemical properties, as well 
as solubility and stability guidelines whilst covering under-
represented areas of fragment space. Furthermore, this library 
covers diverse and typically unrepresented pharmacophores. The 
majority of these 3-D fragments are available for protein screening 
at the Diamond-XChem facility.[39] It is envisaged that the 
workflow demonstrated herein could be applied to many 
analogous potential 3-D fragments and new synthetic 
methodologies, thus enabling the generation of other fit-for-
purpose 3-D fragments.  
 
Figure 3. A: PMI plot of the final fragment collection. Red dots indicate global 
minimum energy conformers and blue dots indicate higher energy conformers. 
B: Cumulative PMI analysis of the fragment collection (light blue) along with six 
commercially available libraries. 
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Thinking in 3D: 56 3-D (rather than sp3-rich) disubstituted pyrrolidine and piperidine fragments were designed and synthesised. 
Computationally generating global minimum energy and higher-energy (but accessible) conformers of potential 3-D fragments and 
assessing their shape by principal moments of inertia analysis prior to synthesis ensured that the collection was significantly three-
dimensional and shape diverse, as demonstrated by comparison with six commercial fragment libraries. The majority of the 3-D 
fragments are ‘rule-of-three’ compliant and all contain synthetic handles for future fragment elaboration.  
 
